$35.36 Million in Sales Expected for Agios Pharmaceuticals Inc (NASDAQ:AGIO) This Quarter

Brokerages expect Agios Pharmaceuticals Inc (NASDAQ:AGIO) to report $35.36 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Agios Pharmaceuticals’ earnings, with estimates ranging from $28.70 million to $40.21 million. Agios Pharmaceuticals posted sales of $26.22 million during the same quarter last year, which suggests a positive year-over-year growth rate of 34.9%. The firm is scheduled to announce its next quarterly earnings results on Thursday, August 6th.

According to Zacks, analysts expect that Agios Pharmaceuticals will report full year sales of $209.41 million for the current year, with estimates ranging from $174.00 million to $244.63 million. For the next fiscal year, analysts forecast that the business will report sales of $385.36 million, with estimates ranging from $155.00 million to $913.34 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Agios Pharmaceuticals.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported ($0.59) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.67) by $1.08. The company had revenue of $87.10 million during the quarter, compared to analysts’ expectations of $31.12 million. Agios Pharmaceuticals had a negative return on equity of 63.85% and a negative net margin of 205.20%. The business’s revenue for the quarter was up 188.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.59) earnings per share.

Several equities research analysts have recently weighed in on AGIO shares. Oppenheimer reaffirmed a “hold” rating on shares of Agios Pharmaceuticals in a research report on Monday, June 15th. BidaskClub raised Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $71.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, April 30th. SVB Leerink upped their target price on Agios Pharmaceuticals from $70.00 to $72.00 and gave the stock an “outperform” rating in a research report on Monday, June 15th. Finally, Citigroup upped their target price on Agios Pharmaceuticals from $64.00 to $75.00 and gave the stock a “buy” rating in a research report on Monday, June 15th. Four equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Agios Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $68.62.

In other Agios Pharmaceuticals news, insider Christopher Bowden sold 3,583 shares of the stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $50.01, for a total transaction of $179,185.83. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.16% of the stock is owned by company insiders.

Institutional investors have recently modified their holdings of the company. Barclays PLC boosted its position in shares of Agios Pharmaceuticals by 595.2% in the fourth quarter. Barclays PLC now owns 23,562 shares of the biopharmaceutical company’s stock worth $1,125,000 after buying an additional 20,173 shares during the period. Credit Suisse AG raised its holdings in shares of Agios Pharmaceuticals by 181.7% during the fourth quarter. Credit Suisse AG now owns 104,198 shares of the biopharmaceutical company’s stock worth $4,976,000 after acquiring an additional 67,215 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Agios Pharmaceuticals by 6.2% during the first quarter. Geode Capital Management LLC now owns 725,185 shares of the biopharmaceutical company’s stock worth $25,729,000 after acquiring an additional 42,314 shares in the last quarter. Thrivent Financial for Lutherans raised its holdings in shares of Agios Pharmaceuticals by 0.3% during the first quarter. Thrivent Financial for Lutherans now owns 269,671 shares of the biopharmaceutical company’s stock worth $9,568,000 after acquiring an additional 938 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of Agios Pharmaceuticals by 11.6% during the first quarter. Principal Financial Group Inc. now owns 15,018 shares of the biopharmaceutical company’s stock worth $533,000 after acquiring an additional 1,565 shares in the last quarter. 97.73% of the stock is owned by institutional investors and hedge funds.

Agios Pharmaceuticals stock opened at $53.48 on Wednesday. The firm has a market capitalization of $3.56 billion, a P/E ratio of -9.11 and a beta of 2.14. The company has a current ratio of 8.41, a quick ratio of 8.27 and a debt-to-equity ratio of 0.17. The stock has a fifty day moving average price of $49.97 and a 200 day moving average price of $46.51. Agios Pharmaceuticals has a 52 week low of $27.77 and a 52 week high of $54.68.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

Further Reading: How to execute a trade ex-dividend strategy?

Get a free copy of the Zacks research report on Agios Pharmaceuticals (AGIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.